The Fazekas score 2, mentioned in a brain MRI report, describes moderate damage to the white matter. This intermediate grade on the Fazekas scale reflects the presence of confluent hyperintensities on T2 FLAIR sequences, located in the deep white matter or in the periventricular area. The question raised by this result is precise: what measurable link exists between this score and cognitive decline in seniors?
Fazekas Score and Cognitive Risk: What the Data Allows Us to Compare
The Fazekas scale classifies white matter lesions into four grades, from 0 (no lesion) to 3 (severe and confluent damage). Grade 2 corresponds to lesions that begin to conflate without occupying the entirety of the deep white matter.
| Fazekas Grade | MRI Description | Documented Cognitive Association |
|---|---|---|
| 0 | No hyperintensity | No association reported |
| 1 | Isolated punctate lesions | Low, often considered related to normal aging |
| 2 | Moderate confluent lesions | Significant association with slowing of executive functions and processing speed |
| 3 | Extensive confluence of white matter | Increased risk of vascular dementia and motor disorders |
This table highlights a threshold: the transition from grade 1 to grade 2 marks a shift between anomalies considered benign and lesions whose impact on cognition becomes statistically measurable. However, a Fazekas 2 does not predict, on its own, the progression to dementia.
To better understand the repercussions of the Fazekas score 2 on cognitive health, it is necessary to go beyond the raw number and examine the topography of the lesions, associated vascular risk factors, and the results of neuropsychological tests.
Topography of Lesions: Why Two Fazekas 2 Scores Are Not Equivalent
The same Fazekas score 2 can cover very different clinical realities. A synthesis published in September 2026 confirms that periventricular hyperintensities are more strongly associated with cognitive performance than isolated deep white matter lesions.
Lesions located in the frontal or periventricular regions disrupt the circuits connecting the prefrontal cortex to the basal ganglia. These circuits are directly involved in executive functions: planning, mental flexibility, inhibition.
In contrast, lesions of the same grade located in the posterior regions or the centrum semiovale may remain silent cognitively for a long time, while affecting gait and balance more. Gait disturbances associated with frontal and periventricular lesions are documented as a complementary clinical indicator of cognitive decline.
The Actual Volume of Lesions Also Matters
The Fazekas scale remains a semi-quantitative visual classification. Two patients classified as Fazekas 2 may present very different lesion volumes if the load of hyperintensities is precisely measured by automated volumetry. The score alone does not capture the total lesion burden, which explains why some Fazekas 2 patients remain stable for years while others decline more rapidly.
Vascular Risk Factors and Progression of White Matter Lesions
Fazekas 2 vascular leukoencephalopathy does not occur in isolation. It is part of small vessel disease, whose main mechanisms are arteriolosclerosis and lipohyalinosis. These processes reduce blood flow in the deep white matter and cause chronic ischemia.
The modifiable risk factors that accelerate the progression of lesions are well identified:
- Hypertension is the factor most consistently associated with the progression of white matter hyperintensities, regardless of the patient’s age.
- Type 2 diabetes exacerbates cerebral microvascular damage through mechanisms combining chronic inflammation and endothelial dysfunction.
- Smoking and dyslipidemia contribute to arteriolar stiffness and accelerate axonal-myelination loss in already weakened areas.
A recent finding deserves attention: a study published in PLOS ONE in September 2026 highlights that white matter abnormalities are common in elderly individuals without dementia. Therefore, the presence of a Fazekas 2 does not mean that cognitive decline is inevitable, but that strict control of vascular factors becomes a clinical priority.
Interpreting a Fazekas 2: The Limits of the Isolated Score
The Fazekas score was designed as a radiological classification tool, not as a standalone prognostic tool. Several elements must be cross-referenced with the grade to assess the actual risk of cognitive decline:
- The results of standardized neuropsychological tests (assessment of working memory, processing speed, executive functions).
- The presence of other markers of small vessel disease: microbleeds, lacunes, dilated perivascular spaces.
- The degree of overall cerebral atrophy, which may coexist with white matter lesions and amplify their impact.
- The existence of a concomitant neurodegenerative pathology, as Fazekas 2 lesions may coexist with early Alzheimer’s disease.
This coexistence complicates the clinical picture. The Fazekas score does not distinguish between the vascular component and the degenerative component in a cognitive disorder observed in a given patient. Therefore, the diagnosis relies on a bundle of clinical, biological, and radiological arguments.
Follow-up MRI and Longitudinal Assessment
A stable Fazekas 2 over time, without progression or the appearance of new vascular markers, has a very different prognostic significance than an evolving Fazekas 2. The comparison of successive MRIs allows for distinguishing an old and stabilized lesion burden from an actively progressing small vessel disease. The trajectory of the lesions matters more than the score at a given moment.
The Fazekas score 2 is a radiological alert signal, not a verdict. Its interpretation depends on the location of the lesions, the actual volume of hyperintensities, the presence of other cerebrovascular markers, and the patient’s vascular risk profile. Controlling hypertension, diabetes, and other modifiable factors remains the most documented lever to slow progression to a more severe stage and preserve cognitive functions for as long as possible.
